Eli Lilly & Co. (NYSE:LLY) announced the launch of a new open innovation platform designed to help build the company's pipeline of tomorrow and, from a philanthropic perspective, identify molecules that may have application for treating multi-drug resistant tuberculosis (MDR-TB).

Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. It offers neuroscience products to treat schizophrenia, manic episodes, and bipolar maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; bulimia nervosa and obsessive-compulsive disorders; and bipolar depression and treatment-resistant depression.

Read the full article and the disclaimer at: http://drstockpick.com/?p=22313